

# Engineering CRISPR guide RNA riboswitches for *in vivo* applications

Roberto Galizi<sup>1</sup>

[r.galizi11@imperial.ac.uk](mailto:r.galizi11@imperial.ac.uk)

Alfonso Jaramillo<sup>2, 3, 4</sup>

[alfonso.jaramillo@synth-bio.org](mailto:alfonso.jaramillo@synth-bio.org)

<sup>1</sup>Department of Life Sciences, Imperial College London, London, United Kingdom

<sup>2</sup>Warwick Integrative Synthetic Biology Centre (WISB) and School of Life Sciences, University of Warwick, CV4 7AL Coventry, United Kingdom

<sup>3</sup>ISSB, CNRS, Univ Evry, CEA, Université Paris-Saclay, 91025 Evry, France

<sup>4</sup>Institute for Integrative Systems Biology (I2SysBio), University of Valencia-CSIC, 46980 Paterna, Spain

---

CRISPR-based genome editing provides a simple and scalable toolbox for a variety of therapeutic and biotechnology applications. Whilst the fundamental properties of CRISPR proved easily transferable from the native prokaryotic hosts to eukaryotic and multicellular organisms, the tight control of the CRISPR-editing activity remains a major challenge. Here we summarise recent developments of CRISPR and riboswitch technologies and recommend novel functionalised synthetic-gRNA (sgRNA) designs to achieve inducible and spatiotemporal regulation of CRISPR-based genetic editors in response to cellular or extracellular stimuli. We believe that future advances of these tools will have major implications for both basic and applied research, spanning from fundamental genetic studies and synthetic biology to genetic editing and gene therapy.

---

**Current Opinion in Biotechnology** 2018, 55:xx-yy

This review comes from a themed issue on **Analytical biotechnology**

Edited by **Saulius Klimasauskas** and **Linas Mazutis**

<https://doi.org/10.1016/j.copbio.2018.08.007>


0958-1669/© 2018 Elsevier Ltd. All rights reserved. Published by Elsevier Ltd.

## Introduction

The microbial adaptive immune system ~~CRISPR~~ (clustered regularly interspaced short palindromic repeats, **CRISPR**) offers a unique and highly effective toolbox for targeted genomic engineering, providing a versatile system to virtually target any nucleic acid sequence of choice with the sole engineering of a short fragment of RNA. In a seminal paper Jinek ~~et al.~~ proposed to harness the nuclease power of the type IIA CRISPR system of *Streptococcus pyogenes* utilizing a single CRISPR associated protein (SpCas9) and a single sgRNA, instead of the two RNAs and the large Cas protein complex found in the original host [1] (Figure 2a). Most of the CRISPR genome editing to date has been carried out with the type II nuclease CRISPR associated protein 9 from *Streptococcus pyogenes* (SpCas9). Redesigned versions were also generated by mutagenizing the key residues that contribute to endonuclease activity [2] and target specificity [3], by producing smaller protein variants [4] or assembling these into subunits to ease its delivery [5]. Furthermore, an increasing number of Cas9 orthologues and related effector proteins have been characterised from diverse bacterial species, some of which exhibit reduced molecular size and different target site specificities [6]. The recently characterised type II CRISPR-associated endonuclease Cpf1, also called 'Cas12a', for instance, shows distinguishing features from SpCas9. Cpf1 requires only a 42-nt CRISPR RNA (crRNA) to find its target instead of the ~100-nt gRNA for SpCas9, recognises a T-rich protospacer-adjacent motif (PAM) [7,8] that is 5' instead of 3' of the target site (precisely TTTV for Cpf1, NGG for SpCas9), has intrinsic RNase activity for the processing of multiple crRNAs from a single transcript [9,10] and makes staggered cuts (5' overhang) whilst Cas9 makes "blunt" blunt cuts in the genome [7]. CRISPR-associated endonuclease and related gRNAs can work heterologously in most species to produce mutagenesis, gene knockin/knockout and chromosome deletion/translocations. If the protein is engineered by knocking out each of its two nickase domains to generate the catalytically inert proteins 'dCas9' and 'dCpf1', the sgRNA:dCas9 (or sgRNA:dCpf1) complex will remain bound to its double-stranded DNA

(dsDNA) substrate [2]. As many other DNA-binding proteins, such as the popular zinc fingers, sgRNA:dCas9 or dCpf1 can work as a transcriptional repressor for CRISPR interfering (CRISPRi) without further engineering [11,12] or by adding transcriptional repression domains such as the Krüppel associated box (KRAB) [13,14]. Deactivated CRISPR-associated endonucleases can be engineered to function as transcriptional activators or epigenetic modifiers other than being utilized for high-resolution genome imaging [15] and DNA/RNA pull-down [16]. Hereafter we will refer to all these variants as CRISPR-editors. At least in theory, it is possible to reprogram CRISPR specificity to recognize any target region flanking a short PAM sequence by simply providing different gRNA-spacers. The PAM therefore represents the sole CRISPR-targetability constraint, which has been shown possible to broaden by mutating the PAM interacting domain of the protein [17,18]. These findings empowered over the recent years a vast range of applications from basic biology to biotechnology and medicine. Nonetheless, several challenges are still hampering the broad applicability, efficiency, specificity and safety of CRISPR-editing systems (Figure 1). Between these, the precise and robust spatiotemporal control of the nucleases activity which, at least for the majority of the current designs, relies solely upon the spatiotemporal specificity of the polymerase II promoter used to transcribe the endonucleases component (generally Cas9 or Cpf1) or it is strictly delivery-procedure dependent when protein or RNA are directly used for the editing [19]. Several strategies to engineer inducible CRISPR systems have been proposed over the recent years (some of these are summarised in Table 1). In the following we will focus on inducible CRISPR systems based on riboswitch regulation by giving an overview of the existing tools, propose new designs and highlight some of the current and foreseen applications.

A)



B)



**Challenges**

Target site selection – Spatiotemporal activity – Resistance – Incidence of HDR  
Off-targets – Delivery – Confinement – Containment

**Figure 1** Applications, evaluation criteria and challenges of CRISPR-mediated editing. (a) Venn diagram showing some of the main CRISPR applications in human health, environment, agriculture and biotech and evaluation criteria (outer circle) [94–96]. (b) CRISPR-editing challenges. Target site selection: target site and PAM specificity. Spatiotemporal activity: e.g. for example, unexpected leaky expression or activity. Resistance to cleavage: pre-existing polymorphisms or *de-novo de novo* mutations generated by end-joining repairing of the target. Incidence of homology directed repair (HDR) versus error prone non-homologous end joining repair. Off-targets: promiscuous cleavage at genomic sequences that have significant similarity to the target. Delivery: particularly relevant for gene therapy applications where a safe and efficient delivery of the CRISPR-editing to specific tissues and cells is an essential requirement. Confinement and containment: physical, reproductive, ecological or molecular barriers to limit CRISPR-editing to the target organisms or species [93,97,98].

alt-text: Figure 1

**Table 1** Inducible CRISPR-editors. (Text repeated) CRISPR editors can be designed to function as: endonucleases, in the form of catalytically active Cas9/Cpf1; transcriptional activators (e.g. dCa9-VP64, dCas9-SAM, dCas9-Suntag, dCas9-VPR) generally referred as CRISPRa (CRISPR activation); transcriptional repressors (e.g. dCas9-only or dCas9-KRAB) also defined as CRISPRi (CRISPR interfering); DNA or histone modifiers, by fusing dCas9 or dCpf1 proteins to histone demethylases (LSD1), histone acetyltransferases (p300), DNA methyltransferases (DNMT3a) or DNA demethylases (TET1) [95,98,99]

alt-text: Table 1

CRISPR-editors			
Endonucleases, activators, repressors, modifiers			
Inducible CRISPR systems		Regulation	
Types	Examples	Exogenous	Endogenous
Cis-regulatory elements	Promoters, enhancers, insulators and silencers (polymerase II or III responsive)		
RNA transcript interactions (riboregulators)	ncRNA	<b>Biological</b>	<b>Source</b>
	Riboswitches	Synthetic or heterologous/pathogenic RNA, DNA, proteins (e.g. transcription factors)	<i>RNA (mRNA or ncRNA)</i> <i>DNA, proteins, pH, temperature</i>
	Toehold switches		
	Switch-gRNA		
Split system	Intein-mediated	<b>Chemical</b>	<b>Type</b> <i>Tissue/cell-specific</i> <i>Cellular state-specific</i> (e.g. quiescent/active, stress response, mutations) <i>Organism/specie-specific</i> (e.g. vector-specific for gene drive applications)
	Rapamycin-mediated	Drugs, small molecules	
	Magnet-mediated		
	Cryptochrome-mediated		
Allosteric system	Conformational change of Cas9/Cpf1		
Combinatorial system	Dimerization	<b>Physical</b>	
	Inducible promoters (tetracycline, doxycycline, etc.)	Light, pH, temperature	
	Recombinase-inducible (Cre)		
Inhibitory molecules	Anti-Cas9 proteins		
	Anti-gRNA		
	gRNA mimics		

CRISPR-editors can be designed to function as: endonucleases, in the form of catalytically active Cas9/Cpf1; transcriptional activators, generally referred as CRISPRa (CRISPR activation) e.g., for example, dCa9-VP64, dCas9-SAM, dCas9-Suntag, dCas9-VPR; transcriptional repressors or CRISPRi (CRISPR interfering) e.g., for example, dCas9-only or dCas9-KRAB; DNA or histone modifiers, by fusing dCas9 or dCpf1 proteins to histone demethylases (LSD1), histone acetyltransferases (p300), DNA methyltransferases (DNMT3a) or DNA demethylases (TET1) [95,98,99].

## Riboregulation and riboswitches: current designs and applications

### Natural and synthetic riboswitches

Riboswitches are structured *cis*-regulatory segments of RNA, mostly found in bacterial messenger RNAs (mRNAs), capable of modulating the gene's protein product in response to small molecules such as specific metabolites. These usually consist of an aptamer domain that binds with high specificity and affinity to a target ligand and transduces the binding signal into a gene expression output. Numerous RNA aptamers have been discovered, showcasing

their intrinsic ability to tightly and selectively recognise specific molecules and to trigger ligand-dependent gene regulation in bacteria, plants and fungi [20]. Riboswitch engineering requires computational analysis and design of aptamers that recognise xenobiotic compounds as well as the development of new testing platforms. In natural riboswitches, the nucleotides within the aptamer domain responsible for ligand binding tend to be evolutionary conserved and when mutated can result in changed ligand specificity, usually by altering the hydrogen-bonding pattern of the domain responsible for ligand recognition. A large number of riboswitch designs are indeed inspired by nature: first, natural purine (guanine and adenine) riboswitches [21,22], widely used to engineer orthogonal gene activation or repression counterparts to generate riboswitch-based controllers of cell behaviour and physiology in bacteria [23,24]; second, PreQ<sub>1</sub> riboswitches from a queuosine precursor, involved in the bacterial transfer RNA (tRNA) function [25,26]; third, Flav<sub>in</sub> mononucleotide riboswitches from Roseoflavin, a natural product whose antibacterial activity involves the targeting of riboswitches [27]. Other classes, such as the cyclic dinucleotide riboswitches (cdiG) were instead identified by bioinformatics analysis as for the highly conserved RNA structured element found upstream 'GEMM motif' (genes for environment, membranes and motility) [28].

The dynamic response and the high affinity for target ligands make riboswitch aptamers particularly suitable to function as recognition domain for the development of RNA-based fluorescent biosensors [29]. Here the riboswitch is fused to a transducer module that activates a signaling domain after ligand binding. Between these, Spinach, Spinach2 and Broccoli aptamers have been widely used to build ligand-responsive biosensors for live-cell imaging of target metabolites by producing a fluorescent output upon addition of a substrate [29-31]. Besides being widely used to engineer biochemical reporters (e.g. responsive to Vitamin B<sub>12</sub> [32] and other enzyme mutants [33,34]), biosensors and for *in vivo* imaging of small molecules, riboswitches have also been engineered to interact with xenobiotic molecules to control gene expression in a wide range of prokaryotic microorganisms (e.g. *Escherichia coli*, *Acinetobacter baumannii*, *Bacillus subtilis*, *Mycobacterium smegmatis*, *Mycobacterium tuberculosis* and other streptomyces and cyanobacterial species [35-40]), yeasts [41-44], fungi [45], plants [46] and mammalian cells [47,48]. Riboswitches are also suitable for the engineering of more complex regulations through the implementation of biochemical logic gates and feedback systems [49-51]. RNA-based biosensors are also extensively used for the engineering of metabolic pathways to optimise the production of small molecules such as industrial and fuel compounds [52], or for the sensing of intracellular behaviours and environmental conditions [53].

## **RNA-responsive riboswitches**

Synthetic *trans*-activating RNAs, generally called 'ribo regulators', are one of the first examples of synthetic translational activators described to function as ligands. When added to the 5'-UTR (untranslated regions), these structures can be used to control gene translation by relaxing the structural blockade of hairpins designed to *cis*-repress ribosomal binding [54,55]. A re-engineered version named as 'toehold' [56 (We would like to include here this citation: "https://doi.org/10.1073/pnas.1203831109")] notably improved the range and the dynamic of post-transcriptional control for the development of RNA-nanodevices to evaluate complex logic circuits in living cells [57]. Longer mRNA transcripts can also function as translational triggers [56 (We would like to include here this citations: "https://doi.org/10.1073/pnas.1203831109" and "https://doi.org/10.1093/nar/gkx698"),57] providing the means to build low-cost diagnostic platforms based on toehold designs [58].

## **Riboswitch designs and validation (This should be same font as the two subtitles above: "Natural and synthetic riboswitches" and "RNA-responsive riboswitches")**

Rational or semi-rational designs can be performed by decoupling expression platforms from the activity of the natural aptamer domain followed by the integration of foreign aptamers that are responsive to different ligands [59]. A major challenge faced during the aptamer screening and selection phase is to address the requirement of maintaining functional gene regulation *in vivo* [60]. For instance, the most common methods to generate riboswitches, such as the *in vitro* systematic evolution of ligands by exponential enrichment (SELEX), can generate aptamers and expression platforms that do not always function *in vivo* [61,62] and therefore require downstream screening steps for a comprehensive characterization of their outputs [63]. Computational modeling offers a valuable option to generate functional riboswitches for *in vivo* applications by using the folding energy of the riboswitch combined with the free energy change resulting from ribosome binding to the RBS [35] or by analysing co-transcriptional RNA-ligand interaction dynamics [64,65,66]. A number of expression platforms have been described over the last few years and classifiable as: first, co-transcriptional regulation, where the ligand-binding attenuates transcription by forming a terminator hairpin (e.g. PreQ<sub>1</sub> riboswitches) [25,26,67] or interfering with rho dependent transcription termination (e.g. the *E. coli thiM* riboswitch and the *Salmonella corA*) [68,69]; second, inhibition of translation, with ligand binding forming an alternative structure that occludes the ribosome-binding site (RBS) and prevents initiation of translation (e.g. *thiC* riboswitch) [70]; third, mRNA degradation, caused by ligand-induced ribozyme activity (e.g. the *Bacillus subtilis glmS* RNA) [71]. Fourthly, RNA splicing regulation, where the ligand binding leads to changes in splice sites to form alternate mature mRNA by addition of open reading frames (ORF), inclusion of premature stop codon (e.g. thiamin pyrophosphate (TPP) riboswitches) [72,73] or via exclusion of the polyadenosine (poly-A) tail followed by mRNA degradation (e.g. flowering plants *THIC* genes) [74,75]. Interestingly, TPP riboswitches are the sole type of natural riboswitches being described in plants, marine protists and fungi [42]. There are examples of artificial expression platforms shown to function in eukaryotes such as: first, ribosome blocking, where the aptamer-ligand interaction inhibits the ribosome scanning from the 5' 7-methylguanosine cap to the translation start site preventing translation in yeast (it is yet to be confirmed whether the mammalian ribosomes may or not be able to scan through structured RNAs positioned upstream the start codon [76]); second, ligand-responsive ribozymes (also called 'aptazymes') to promote cleavage of 5'-UTRs (untranslated regions), where the loss of the 5'-cap prevents ribosome initiation, or 3'-UTRs followed by loss of the poly-A tail and degradation of the mRNA transcript [47,48,77]; third, aptazymes associated to micro RNA (miRNA) precursors [78,79] or orthogonal tRNAs for unnatural amino acid incorporation and studies of ribosome function (e.g. T box riboswitches) [37].


Riboswitches and toehold riboregulators have been engineered for a wide number of applications from basic genetic studies to the production of synthetic compounds and diagnostic tests [53,80-82]. Beyond addressing the technical limitations,

one of the major and most exciting challenges is the development of novel approaches that would allow to broaden the use of riboswitches to eukaryotic systems, currently hindered by the cell-specific properties of aptamers or ligands, and the significant differences between the transcription and translation machinery employed by prokaryotic and eukaryotic systems.

In the following, we will describe how novel riboswitch designs can be combined with the pre-existing CRISPR-editing components to engineer specific and sensitive molecular tools to achieve targeted and inducible genetic editing in a wide range of prokaryotic and eukaryotic hosts. We believe that these technologies could be potentially transferrable to any CRISPR-based application.


## CRISPR gRNA riboswitches: new designs and future applications

Riboswitches have been extensively engineered to control gene expression by incorporating aptamers that, after ligand binding, produce a conformational change to trigger the expression of a downstream gene. A similar strategy can be applied to sense CRISPR-sgRNAs (Figure 2a) by grafting an aptamer domain into an allosteric structure that hybridises and obliterates the sgRNA binding to the target. The interaction with the ligand stabilises the aptamer to create a conformational change where the guide sequence is fully exposed. This has already been tested successfully in eukaryotes using Cas9 [83] or Cpf1 [14]. We have also adapted theophylline sensing designs previously developed in our lab [77,84] to generate sgRNAs in *E. coli* (unpublished) (Figure 2b). Aptazymes developed to create UTR-linked riboswitches (described above) can be adapted to control sgRNA activity by adding the corresponding sequence to its 5'-end to repress the guide sequence in the unbound conformation and reconstitute the active conformation after ligand binding (Figure 2c) [85\*,86]. Potentially any ligand-responsive riboswitch could be adapted for sgRNA sensing. For example, light or temperature sensing sgRNA could be generated by replacing the aptamers in the designs represented in Figure 2B and 2C with an aptamer that interacts with a photo-switchable molecule [87] or using temperature riboswitches to regulate the initiation of translation or the transcription termination [88]. The main limitation of CRISPR-based riboswitches is represented by the nature and properties of the ligand-aptamer interaction. If RNA molecules are adapted to function as a trigger to sense sgRNA activity, these molecular tools could be utilized to regulate CRISPR-editing activity in response to endogenous or exogenous RNAs and, at least in theory, could be used for any application and organism where specific spatiotemporal or conditional regulation may be required.



**Figure 2** CRISPR gRNA riboswitch designs. **(a)** Diagram showing the interruption of transcription elongation when the dCas9 (or dCpf1, details not shown here) endonuclease binds to the PAM sequence, unwinds the dsDNA and the guide sequence region, and the gRNA binds to its target in the non-template strand or generates a double-strand break when the active Cas9 (or Cpf1) is used. **(b)** The gRNA is designed with an extra sequence at the 5'-end that hybridises with the guide sequence, which prevents the binding of the gRNA-endonuclease complex to its target. Addition of the theophylline ligand during gRNA transcription stabilises an open conformation with free guide sequence, which will repress transcription after binding to the inactivated protein or cleavage with the active nuclease. **(c)** Design of a gRNA with a non-functional ribozyme on its 5'-end hybridising with the guide sequence. Binding of the ligand stabilises the ribozyme, which self-cleaves and the gRNA with free guide sequence will complex to the protein for repression or cleavage. These designs could be also adapted to dCas9 or dCpf1 linked to activators (e.g. VP64, SAM, Suntag, VPR), repressors for CRISPR interfering (e.g. KRAB), DNA or histone modifiers (e.g. histone demethylase LSD1, histone acetyltransferase p300, DNA methyltransferase DNMT3a, DNA demethylase TET1).

With this aim, we designed *cis*-repressed switching-sgRNA, termed ‘interacting guide RNA’ (igRNA) that change conformation and switch to their active forms upon the binding of trigger-RNAs (trRNA) in the form of sRNA or mRNA. The first approach is based on previously described synthetic riboregulator properties [89], where the trRNA-igRNA pair is analogous to a *trans* activating riboregulator-5′-UTR pair. Here the trRNA strand directly hybridises with the guide counterpart hampering the flexibility of guide and trigger sequence design (Figure 3Aa). To overcome this limitation the stem loop can be redesigned to flank the clamp sequence with two variable regions that hybridise with the trigger sequence (Figure 3Ab). The strategies in Figure 2b and c could also be adapted by replacing the ligand with a trRNA to stabilise the sgRNA stem to its open conformation (Figure 3c and d). Leveraging the intrinsic multiplex capacity of the Cpf1 platform, the designs proposed in Figure 3 could also be adapted to Cpf1 gRNAs to streamline the engineering of complex genetic circuits for gene perturbation studies [90-92] and for a number of other applications where inducible and multiplexed CRISPR-editing activity may be required (Figure 1). We are currently applying our RNA-triggered igRNA designed to sense the cell state in *E. coli* and in mosquito vectors of infectious diseases to activate CRISPR-Cas endonucleases in response to tissue specific endogenous transcripts.



**Figure 3** Endogenous or exogenous RNA could be sensed by a switchable ‘interacting guide RNA’ (igRNA). **(a)** Design of a gRNA with upstream sequence hybridising against the guide sequence. When a trigger RNA (trRNA) is present during gRNA transcription, the trigger sequence binds to the gRNA stabilising a conformation where the guide sequence is freed. The complex binds to the dCas9 (or dCpf1) to repress transcription of a gene containing the target sequence (that is also complementary to the trigger in this case) or to generate double-strand break if the active endonucleases are used. **(b)** Modification of the previous design, where part of the guide sequence is initially hybridised, but the regions complementary to the trRNA are only in the exposed 5′-end and loop, and not in the region hybridising to the target sequence. This allows the design of universal target sequences with no trRNA or gRNA-target constraints. **(c)** The strategy in Figure 2b, where the ligand (here the trRNA) stabilises a conformation in which the gRNA sequence is no longer hybridised. **(d)** The strategy in Figure 2c, where a destabilised hammerhead ribozyme gets reconstituted after binding to the trRNA. As for the configurations represented in Figure 2, also these designs could be adapted to any other type of Cas9 or Cpf1 CRISPR-editor that may function as inducible endonuclease, transcriptional activator or repressors, DNA or histone modifier.

## Conclusions

Non-coding RNAs have been engineered for a wide range of applications and it has been shown recently that similar techniques can be used to engineer gRNAs able to interface with the cellular environment by sensing small-molecules, temperature and light. We have described gRNAs with allosteric properties that allow for signal transduction, cascading, computation, as well as the monitoring and actuation of the transcriptome. The CRISPR-gRNA strategies described here could also be combined among themselves or with other regulatory systems (Table 1) to tackle complex roadblocks that are still hindering CRISPR-editing technologies (Figure 1). We envision that igRNA

riboswitches have great potentials for broadening the variety of applications beyond the development of components for standard biotechnology purposes. CRISPR-based riboswitches represent a versatile *in vivo* post-transcriptional regulation toolbox for the engineering of customizable and highly specific CRISPR-editors that can be designed for targeted genome editing, transcriptional activation/repression or epigenome modification and imaging, exclusively within specific cells, tissues or species where the triggering molecular component is present. The CRISPR-igRNA designs overviewed in [Figure 3](#) could be used to achieve spatiotemporal control of eukaryotic genome editing in response to RNA transcripts that may be specific for: first, pathogenic conditions, such as invading viral RNAs, mRNA transcripts carrying pathogenic mutations or produced upon cellular stress conditions etc.; second, tissue/cell, developmental stage or condition, for applications spanning from gene therapy all the way to the genetic control of invasive species such as malaria transmitting mosquitoes. Here the igRNA could be designed to generate more effective CRISPR-based gene drives by restricting the CRISPR-nuclease activity to the germline [93], generate self-contained gene drive systems active only in laboratory strains (e.g. by using synthetic mRNA triggers not present in wild-type species) or even to engineer suicidal transgenes that respond to specific adverse gene mutations (such as the ones causing insecticide resistance in the mosquitoes).

Whilst we believe that ad hoc computational tools and novel *in vivo* based selection methods will be required, we envision that the development of CRISPR-gRNA based riboswitches designs described here will be extremely valuable to tackle most of the challenges that are still impeding the deployment of CRISPR-mediated genome editing and engineering.

## Conflict of interest statement

Nothing declared.

## References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

## Acknowledgements

This work was supported by grants from the European Commission FP7-ICT-FET-610730 (EVOPROG), FP7-KBBE-613745 (PROMYS), H2020 Marie Skłodowska-Curie 642738 (MetaRNA), EPSRC-BBSRC BB/M017982/1 (WISB center), BBSRC grant EVO-ENGINE BB/P020615/1 and the startup allocation from the School of Life Sciences.

## References

1. M. [Jinek](#), [K. Chylinski](#), [I. Fonfara](#), [M. Hauer](#), [J.A. Doudna](#) and [E. Charpentier](#), A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, *Science* **337**, 2012, 816–821.
2. L.S. [Qi](#), [M.H. Larson](#), [L.A. Gilbert](#), [J.A. Doudna](#), [J.S. Weissman](#), [A.P. Arkin](#) and [W.A. Lim](#), Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression, *Cell* **152**, 2013, 1173–1183.
3. B.P. [Kleinstiver](#), [V. Pattanayak](#), [M.S. Prew](#), [S.Q. Tsai](#), [N. Nguyen](#), [Z. Zheng](#) and [J.K. Joung](#), High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets, *Nature* **529**, 2016, 490–495.
4. E. [Kim](#), [T. Koo](#), [S.W. Park](#), [D. Kim](#), [K. Kim](#), [H.-Y. Cho](#), [D.W. Song](#), [K.T. Lee](#), [M.H. Jung](#), [S. Kim](#), et al., *In vivo* genome editing with a small Cas9 orthologue derived from *Campylobacter jejuni*, *Nat Commun* **8**, 2017, 14500.
5. B. [Zetsche](#), [S.E. Volz](#) and [E. Zhang](#), A split-Cas9 architecture for inducible genome editing and transcription modulation, *Nat Biotechnol* 2015, <https://doi.org/10.1038/nbt.3149>.
6. [A. Cebrian-Serrano](#) and [B. Davies](#), CRISPR-Cas orthologues and variants: optimizing the repertoire, specificity and delivery of genome engineering tools, *Mamm Genome* **28**, 2017, 247–261.
7. B. [Zetsche](#), [J.S. Gootenberg](#), [O.O. Abudayyeh](#), [I.M. Slaymaker](#), [K.S. Makarova](#), [P. Essletzbichler](#), [S.E. Volz](#), [J. Joung](#), [J. van der Oost](#), [A. Regev](#), et al., Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system, *Cell* **163**, 2015, 759–771.
8. L. [Gao](#), [D.B.T. Cox](#), [W.X. Yan](#), [J.C. Manteiga](#), [M.W. Schneider](#), [T. Yamano](#), [H. Nishimasu](#), [O. Nureki](#), [N. Crosetto](#) and [E. Zhang](#), Engineered Cpf1 variants with altered PAM specificities, *Nat Biotechnol* **35**, 2017, 789–792.
9. B. [Zetsche](#), [M. Heidenreich](#), [P. Mohanraju](#), [I. Fedorova](#), [J. Kneppers](#), [E.M. DeGennaro](#), [N. Winblad](#), [S.R. Choudhury](#), [O.O. Abudayyeh](#), [J.S. Gootenberg](#), et al., Multiplex gene editing by CRISPR-Cpf1 through autonomous processing of a single crRNA array, *Nat Biotechnol* **35**, 2017, 31–34.



10. I. Fonfara, H. Richter, M. Bratovič, A.L. Rhun and E. Charpentier, The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA, *Nature* **532**, 2016, 517-521.
11. D. Bikard, W. Jiang, P. Samai, A. Hochschild, F. Zhang and L.A. Marraffini, Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system, *Nucleic Acids Res* **41**, 2013, 7429-7437.
12. X. Zhang, J. Wang, Q. Cheng, X. Zheng, G. Zhao and J. Wang, Multiplex gene regulation by CRISPR-ddCpf1, *Cell Discov* **3**, 2017, 17018.
13. L.A. Gilbert, M.H. Larson, L. Morsut, Z. Liu, G.A. Brar, S.E. Torres, N. Stern-Ginossar, O. Brandman, E.H. Whitehead, J.A. Doudna, et al., CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes, *Cell* **154**, 2013, 442-451.
14. Y. Liu, J. Han, Z. Chen, H. Wu, H. Dong and G. Nie, Engineering cell signaling using tunable CRISPR-Cpf1-based transcription factors, *Nat Commun* **8**, 2017, 2095. **F. T (please add spacing between reference and description)** The catalytically dead Cpf1 endonuclease from *Acidaminococcus* can function in human cells as a transcriptional regulator and signal conductor to build programmable ligand-controlled cell signaling circuits through the use of crRNAs with engineered riboswitches or G protein-coupled receptors linked to the dAsCpf1 protein.
15. B. Chen, J. Hu, R. Almeida, H. Liu, S. Balakrishnan, C. Covill-Cooke, W.A. Lim and B. Huang, Expanding the CRISPR imaging toolset with *Staphylococcus aureus* Cas9 for simultaneous imaging of multiple genomic loci, *Nucleic Acids Res* **44**, 2016, e75. Engineered SpCas9 and SaCas9 proteins for multiplexed imaging of endogenous genomic sequences to resolve specific genomic loci.
16. X. Liu, Y. Zhang, Y. Chen, M. Li, F. Zhou, K. Li, H. Cao, M. Ni, Y. Liu, Z. Gu, et al., In situ capture of chromatin interactions by biotinylated dCas9, *Cell* **170**, 2017, 1028-1043.e19.
17. B.P. Kleinstiver, M.S. Prew, S.O. Tsai, N.T. Nguyen, V.V. Topkar, Z. Zheng and J.K. Joung, Broadening *Staphylococcus aureus* Cas9 targeting range by modifying PAM recognition, *Nat Biotechnol* **33**, 2015, 1293-1298.
18. J.H. Hu, S.M. Miller, M.H. Geurts, W. Tang, L. Chen, N. Sun, C.M. Zeina, X. Gao, H.A. Rees, Z. Lin, et al., Evolved Cas9 variants with broad PAM compatibility and high DNA specificity, *Nature* **556**, 2018, 57-63. Phage-assisted continuous evolution to generate novel SpCas9 proteins with a wider range of PAM specificity. The broadest version characterized is the xCas9, which can recognize NG, GAA and GAT PAM sequences between others, and shows greater DNA specificity compared to the SpCas9.
19. E. Kouranova, K. Forbes, G. Zhao, J. Warren, A. Bartels, Y. Wu and X. Cui, CRISPRs for optimal targeting: delivery of CRISPR components as DNA, RNA, and protein into cultured cells and single-cell embryos, *Hum Gene Ther* **27**, 2016, 464-475.
20. S. Tapsin, M. Sun, Y. Shen, H. Zhang, X.N. Lim, T.T. Susanto, S.L. Yang, G.S. Zeng, J. Lee, A. Lezhava, et al., Genome-wide identification of natural RNA aptamers in prokaryotes and eukaryotes, *Nat Commun* **9**, 2018, 1289. Novel genome-wide strategy called PARCEL for high-throughput identification of RNA aptamers *in vitro* *in vitro*. A total of 58 highly structured and conserved RNA aptamers were identified and unexpectedly prevalent in coding regions.
21. M. Mandal and R.R. Breaker, Adenine riboswitches and gene activation by disruption of a transcription terminator, *Nat Struct Mol Biol* **11**, 2004, 29-35.
22. R.T. Batey, S.D. Gilbert and R.K. Montange, Structure of a natural guanine-responsive riboswitch complexed with the metabolite hypoxanthine, *Nature* **432**, 2004, 411-415.
23. S.D. Gilbert, F.E. Reyes, A.L. Edwards and R.T. Batey, Adaptive ligand binding by the purine riboswitch in the recognition of guanine and adenine analogs, *Struct Lond Engl* **17**, 2009, 857-868.
24. H.A. Vincent, C.J. Robinson, M.-C. Wu, N. Dixon and J. Micklefield, Generation of orthogonally selective bacterial riboswitches by targeted mutagenesis and in vivo screening, *Methods Mol Biol Clifton NJ* **1111**, 2014, 107-129.
25. P.J. McCown, J.J. Liang, Z. Weinberg and R.R. Breaker, Structural, functional, and taxonomic diversity of three PreQ1 riboswitch classes, *Chem Biol* **21**, 2014, 880-889.
26. M.-C. Wu, P.T. Lowe, C.J. Robinson, H.A. Vincent, N. Dixon, J. Leigh and J. Micklefield, Rational re-engineering of a transcriptional silencing PreQ1 riboswitch, *J Am Chem Soc* **137**, 2015, 9015-9021. Rational targeted approach to re-engineer the PreQ1 riboswitch from *Bacillus subtilis* into an orthogonal OFF-switch.
27. E.R. Lee, K.F. Blount and R.R. Breaker, Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression, *RNA Biol* **6**, 2009, 187-194.
28. C.A. Kellenberger, S.C. Wilson, S.F. Hickey, T.L. Gonzalez, Y. Su, Z.F. Hallberg, T.F. Brewer, A.T. Iavarone, H.K. Carlson, Y.-F. Hsieh, et al., GEMM-I riboswitches from *Geobacter* sense the bacterial second messenger cyclic



AMP-GMP, *Proc Natl Acad Sci U S A* **112**, 2015, 5383-5388.

29. X.C. Wang, S.C. Wilson and M.C. Hammond, Next-generation RNA-based fluorescent biosensors enable anaerobic detection of cyclic di-GMP, *Nucleic Acids Res* **44**, 2016, e139. RNA-based fluorescent biosensor designs, selectively responding to cyclic di-GMP, to study host-microbial interactions via small molecule signaling.
30. J. Ouellet, RNA fluorescence with light-up aptamers, *Front Chem* **4**, 2016.
31. A. Autour, E. Westhof and M. Ryckelynck, iSpinach: a fluorogenic RNA aptamer optimized for in vitro applications, *Nucleic Acids Res* **44**, 2016, 2491-2500.
32. C.C. Fowler, E.D. Brown and Y. Li, Using a riboswitch sensor to examine coenzyme B12 metabolism and transport in *E. coli*, *Chem Biol* **17**, 2010, 756-765.
33. J. Yang, S.W. Seo, S. Jang, S.-I. Shin, C.H. Lim, T.-Y. Roh and G.Y. Jung, Synthetic RNA devices to expedite the evolution of metabolite-producing microbes, *Nat Commun* **4**, 2013, 1413.
34. H. Xiao, Z. Bao and H. Zhao, High throughput screening and selection methods for directed enzyme evolution, *Ind Eng Chem Res* **54**, 2015, 4011-4020.
35. A. Espah Borujeni, D.M. Mishler, J. Wang, W. Huso and H.M. Salis, Automated physics-based design of synthetic riboswitches from diverse RNA aptamers, *Nucleic Acids Res* **44**, 2016, 1-13. Interesting statistical thermodynamic model to predict sequence-structure-function relationships of riboswitches for gene activation.
36. E. Mehdizadeh Aghdam, M.S. Hejazi and A. Barzegar, Riboswitches: from living biosensors to novel targets of antibiotics, *Gene* **592**, 2016, 244-259.
37. A.V. Sherwood, J.K. Frandsen, F.J. Grundy and T.M. Henkin, New tRNA contacts facilitate ligand binding in a *Mycobacterium smegmatis* T box riboswitch, *Proc Natl Acad Sci U S A* **2018**, <https://doi.org/10.1073/pnas.1721254115>. Identification of interaction sites involved in tRNA recognition by the T box riboswitches that regulate expression of amino acid-related genes.
38. W. Cui, L. Han, J. Cheng, Z. Liu, L. Zhou, J. Guo and Z. Zhou, Engineering an inducible gene expression system for *Bacillus subtilis* from a strong constitutive promoter and a theophylline-activated synthetic riboswitch, *Microb Cell Factories* **15**, 2016.
39. A.T. Ma, C.M. Schmidt and J.W. Golden, Regulation of gene expression in diverse cyanobacterial species by using theophylline-responsive riboswitches, *Appl Environ Microbiol* **80**, 2014, 6704-6713.
40. M.M. Rudolph, M.-P. Vockenhuber and B. Suess, Synthetic riboswitches for the conditional control of gene expression in *Streptomyces coelicolor*, *Microbiology* **159**, 2013, 1416-1422.
41. M. Felletti, J. Stifel, L.A. Wurmthaler, S. Geiger and J.S. Hartig, Twister ribozymes as highly versatile expression platforms for artificial riboswitches, *Nat Commun* **7**, 2016. The small endonucleolytic twister ribozyme provides a versatile expression platform for the engineering of a number of one-input and two-input regulators of gene expression in both bacteria and yeast, also suggesting a natural role of this widespread ribozyme class.
42. P.D. Donovan, L.M. Holland, L. Lombardi, A.Y. Coughlan, D.G. Higgins, K.H. Wolfe and G. Butler, TPP riboswitch-dependent regulation of an ancient thiamin transporter in *Candida*, *PLoS Genet* **14**, 2018. The thiamin pyrophosphate (TPP) riboswitches are widespread in the budding yeasts (*Saccharomycotina*) and common in homologs of *DUR31*, including *Candida parapsilosis* where the authors demonstrate its molecular function.
43. M.A. Moldovan, S.A. Petrova and M.S. Gelfand, Comparative genomic analysis of fungal TPP-riboswitches, *Fungal Genet Biol* **114**, 2018, 34-41.
44. F. Groher, C. Boffill-Bosch, C. Schneider, J. Braun, S. Jager, K. Geißler, K. Hamacher and B. Suess, Riboswitching with ciprofloxacin—development and characterization of a novel RNA regulator, *Nucleic Acids Res* **46**, 2018, 2121-2132.
45. S. Mukherjee, M.D. Retwitzer, D. Barash and S. Sengupta, Phylogenomic and comparative analysis of the distribution and regulatory patterns of TPP riboswitches in fungi, *Sci Rep* **8**, 2018, 5563.
46. S.E. Bocobza and A. Aharoni, Small molecules that interact with RNA: riboswitch-based gene control and its involvement in metabolic regulation in plants and algae, *Plant J Cell Mol Biol* **79**, 2014, 693-703.
47. P. Ketzer, J.K. Kaufmann, S. Engelhardt, S. Bossow, C. von Kalle, J.S. Hartig, G. Ungerechts and D.M. Nettelbeck, Artificial riboswitches for gene expression and replication control of DNA and RNA viruses, *Proc Natl Acad Sci U S A* **111**, 2014, E554-E562.


48. G. [Zhong](#), [H. Wang](#), [C.C. Bailey](#), [G. Gao](#) and [M. Farzan](#), Rational design of aptazyme riboswitches for efficient control of gene expression in mammalian cells, *eLife* **5**, 2016. Rational-design approach for the rapid development of *cis*-acting aptazyme riboswitches coupled with a scoring system to predict their activity based on hydrogen bonding, base stacking, and distance to the enzymatic core.
49. J.R. [Rubens](#), [G. Selvaggio](#) and [T.K. Lu](#), Synthetic mixed-signal computation in living cells, *Nat Commun* **7**, 2016. Clever example of combined analogue and digital computation to implement complex hybrid synthetic genetic circuits in living cells.
50. M.E. [Sherlock](#), [N. Sudarsan](#), [S. Stav](#) and [R.R. Breaker](#), Tandem riboswitches form a natural Boolean logic gate to control purine metabolism in bacteria, *eLife* **7**, 2018. First report of riboswitch aptamers for phosphoribosyl pyrophosphate (PRPP) that is naturally existing as single arrangements or in tandem with guanine aptamers. The latter can bind the target ligands, either independently or in combination, to regulate mRNA transcription for *de-novo de novo* purine biosynthesis in bacteria.
51. Y. [Liu](#), [J. Li](#), [Z. Chen](#), [W. Huang](#) and [Z. Cai](#), Synthesizing artificial devices that redirect cellular information at will, *eLife* **7**, 2018. **Description Description** of an ingenious method based on tandem RNA devices to connect one signal to another at the translational level. These designs were used to construct logic gates, incorporate feedback loops into gene networks, recreate signaling pathways and rewire pre-existing such as the oncogenic signaling to reverse the malignant phenotypes of cancer cells.
52. Y. [Liu](#), [Y. Liu](#) and [M. Wang](#), Design, optimization and application of small molecule biosensor in metabolic engineering, *Front Microbiol* **8**, 2017.
53. H.L. [Pham](#), [A. Wong](#), [N. Chua](#), [W.S. Teo](#), [W.S. Yew](#) and [M.W. Chang](#), Engineering a riboswitch-based genetic platform for the self-directed evolution of acid-tolerant phenotypes, *Nat Commun* **8**, 2017. **Engineering Engineering** of a set of pH-sensing riboswitches to control gene expression according to environmental pH and to provide high-resolution recording of host cell exposure to discrete external pH levels. The digital pH-sensing was also applied to the evolutionary engineering of host cells to generate improved tolerance to a broad spectrum of organic acids for metabolic engineering and bioremediation applications.
54. J.C. [Liang](#), [A.L. Chang](#), [A.B. Kennedy](#) and [C.D. Smolke](#), A high-throughput, quantitative cell-based screen for efficient tailoring of RNA device activity, *Nucleic Acids Res* **40**, 2012, e154.
55. L. [Bastet](#), [P. Turcotte](#), [J.T. Wade](#) and [D.A. Lafontaine](#), Maestro of regulation: riboswitches orchestrate gene expression at the levels of translation, transcription and mRNA decay, *RNA Biol* 2018, <https://doi.org/10.1080/15476286.2018.1451721>.
56. **(Please add these two citations as highlighted in the text: ••"https://doi.org/10.1073/pnas.1203831109" followed by description "Automated design and validation of riboregulatory devices to create complex logic circuits in living cells". And ••"https://doi.org/10.1093/nar/gkx698" followed by the description "Implementation of portable sRNA-regulated networks for the engineering of complex cellular programs and biological computations".)** A.A. [Green](#), [P.A. Silver](#), [J.J. Collins](#) and [P. Yin](#), Toehold switches: de-novo-designed regulators of gene expression, *Cell* **159**, 2014, 925-939. **First report of d De novo**-designed prokaryotic riboregulators, named as toeholds, to activate (independently and orthogonally) gene expression in response to cognate RNAs, including endogenous RNAs
57. •• A.A. [Green](#), [J. Kim](#), [D. Ma](#), [P.A. Silver](#), [J.J. Collins](#) and [P. Yin](#), Complex cellular logic computation using ribocomputing devices, *Nature* **548**, 2017, 117-121. **Elegant strategy Strategy** for constructing post-transcriptional RNA-only nanodevices to evaluate and compute complex logic in living cells through predictable and designable base-pairing rules.
58. K. [Pardee](#), [A.A. Green](#), [M.K. Takahashi](#), [D. Braff](#), [G. Lambert](#), [J.W. Lee](#), [T. Ferrante](#), [D. Ma](#), [N. Donghia](#), [M. Fan](#), et al., Rapid, low-cost detection of Zika virus using programmable biomolecular components, *Cell* **165**, 2016, 1255-1266. **Cell-free Cell-free**, paper-based sensors for the detection of the Zika virus RNA genome by linking isothermal RNA amplification to toehold switch RNA sensors. When coupled with a CRISPR/Cas9-based module, the sensor can discriminate between viral strains with single-base resolution.
59. P. [Ceres](#), [A.D. Garst](#), [J.G. Marcano-Velázquez](#) and R.T. Batey, Modularity of select riboswitch expression platforms enables facile engineering of novel genetic regulatory devices, *ACS Synth Biol* **2**, 2013, 463-472.
60. B. [Suess](#) and [J.E. Weigand](#), Engineered riboswitches: overview, problems and trends, *RNA Biol* **5**, 2008, 24-29.
61. A.D. [Ellington](#) and [J.W. Szostak](#), In vitro selection of RNA molecules that bind specific ligands, *Nature* **346**, 1990, 818-822.
62. Z. [Zhuo](#), [Y. Yu](#), [M. Wang](#), [J. Li](#), [Z. Zhang](#), [J. Liu](#), [X. Wu](#), [A. Lu](#), [G. Zhang](#) and [B. Zhang](#), Recent advances in SELEX technology and aptamer applications in biomedicine, *Int J Mol Sci* **18**, 2017.
63. S.V. [Harbaugh](#), [J.A. Martin](#), [J. Weinstein](#), [G. Ingram](#) and [N. Kelley-Loughnane](#), Screening and selection of artificial riboswitches, *Methods* 2018, <https://doi.org/10.1016/j.ymeth.2018.05.012>.

64. J. Chappell, A. Westbrook, M. Verosloff and J.B. Lucks, Computational design of small transcription activating RNAs for versatile and dynamic gene regulation, *Nat Commun* **8**, 2017. **Computational Computational** approach for the creation of a bacterial regulator called small transcription activating RNAs (STARs) that achieve up to ~9000-fold gene activation. Designed STARs were used to reprogram cellular phenotypes, to control multigenic metabolic pathways and in combination with CRISPRi.
65. M.T. Wolfinger, C. Flamm and I.L. Hofacker, Efficient computation of co-transcriptional RNA-ligand interaction dynamics, *Methods* 2018, <https://doi.org/10.1016/j.ymeth.2018.04.036>. **Implementation Implementation** for computational analysis of co-transcriptional RNA-ligand interaction dynamics to model concentration-dependent metabolite binding/unbinding kinetics.
66. Z. Weinberg, J.W. Nelson, C.E. Lünse, M.E. Sherlock and R.R. Breaker, Bioinformatic analysis of riboswitch structures uncovers variant classes with altered ligand specificity, *Proc Natl Acad Sci U S A* **114**, 2017, E2077-E2085. **Novel Novel** method to find riboswitch variants with altered ligand specificity by using multiple-sequence alignments, atomic-resolution, structural information and riboswitch gene associations.
67. W. Winkler, A. Nahvi and R.R. Breaker, Thiamine derivatives bind messenger RNAs directly to regulate bacterial gene expression, *Nature* **419**, 2002, 952-956.
68. L. Bastet, A. Chauvier, N. Singh, A. Lussier, A.-M. Lamontagne, K. Prévost, E. Massé, J.T. Wade and D.A. Lafontaine, Translational control and Rho-dependent transcription termination are intimately linked in riboswitch regulation, *Nucleic Acids Res* **45**, 2017, 7474-7486. **Experimental Experimental** evidence suggesting that the majority of known *E. coli* riboswitches employ the Rho transcription factor to control transcription termination and regulate mRNA levels.
69. M.A. Kriner and E.A. Groisman, RNA secondary structures regulate three steps of Rho-dependent transcription termination within a bacterial mRNA leader, *Nucleic Acids Res* **45**, 2017, 631-642.
70. A. Chauvier, F. Picard-Jean, J.-C. Berger-Dancause, L. Bastet, M.R. Naghdi, A. Dubé, P. Turcotte, J. Perreault and D.A. Lafontaine, Transcriptional pausing at the translation start site operates as a critical checkpoint for riboswitch regulation, *Nat Commun* **8**, 2017. **First First** demonstration of transcriptional pausing at translation start sites described within the *E. coli* thiamin pyrophosphate (TPP) thiC riboswitch that acts as a checkpoint for thiC gene regulation.
71. J.A. Collins, I. Irnov, S. Baker and W.C. Winkler, Mechanism of mRNA destabilization by the glmS ribozyme, *Genes Dev* **21**, 2007, 3356-3368.
72. M.T. Cheah, A. Wachter, N. Sudarsan and R.R. Breaker, Control of alternative RNA splicing and gene expression by eukaryotic riboswitches, *Nature* **447**, 2007, 497-500.
73. M.T. Croft, M. Moulin, M.E. Webb and A.G. Smith, Thiamine biosynthesis in algae is regulated by riboswitches, *Proc Natl Acad Sci U S A* **104**, 2007, 20770-20775.
74. S. Bocobza, A. Adato, T. Mandel, M. Shapira, E. Nudler and A. Aharoni, Riboswitch-dependent gene regulation and its evolution in the plant kingdom, *Genes Dev* **21**, 2007, 2874-2879.
75. A. Wachter, M. Tunc-Ozdemir, B.C. Grove, P.J. Green, D.K. Shintani and R.R. Breaker, Riboswitch control of gene expression in plants by splicing and alternative 3' end processing of mRNAs, *Plant Cell* **19**, 2007, 3437-3450.
76. J.R. Babendure, Control of mammalian translation by mRNA structure near caps, *RNA* **12**, 2006, 851-861.
77. S. Shen, G. Rodrigo, S. Prakash, E. Majer, T.E. Landrain, B. Kirov, J.-A. Daròs and A. Jaramillo, Dynamic signal processing by ribozyme-mediated RNA circuits to control gene expression, *Nucleic Acids Res* **43**, 2015, 5158-5170. **Biochemical Biochemical** strategy to design switchable RNA domains for RNA-mediated signal transduction cascades through strand-displacement and the sensing of small molecules and small RNAs.
78. D. Kumar, C.-I. An and Y. Yokobayashi, Conditional RNA interference mediated by allosteric ribozyme, *J Am Chem Soc* **131**, 2009, 13906-13907.
79. C.L. Beisel, Y.Y. Chen, S.J. Culler, K.G. Hoff and C.D. Smolke, Design of small molecule-responsive microRNAs based on structural requirements for Drosha processing, *Nucleic Acids Res* **39**, 2011, 2981-2994.
80. P. Machtel, K. Bąkowska-Żywicka and M. Żywicki, Emerging applications of riboswitches—from antibacterial targets to molecular tools, *J Appl Genet* **57**, 2016, 531-541.
81. Z.F. Hallberg, Y. Su, R.Z. Kitto and M.C. Hammond, Engineering and in vivo applications of riboswitches, *Annu Rev Biochem* **86**, 2017, 515-539.
82. J. Chappell, K.E. Watters, M.K. Takahashi and J.B. Lucks, A renaissance in RNA synthetic biology: new mechanisms, applications and tools for the future, *Curr Opin Chem Biol* **28**, 2015, 47-56.

83. Y. Liu, Y. Zhan, Z. Chen, A. He, J. Li, H. Wu, L. Liu, C. Zhuang, J. Lin, X. Guo, et al., Directing cellular information flow via CRISPR signal conductors, *Nat Methods* **13**, 2016, 938-944. [CRISPR-sgRNAs](#) [CRISPR-sgRNAs](#) based riboswitches that recognize specific signals to regulate transcription of endogenous genes in response to external or internal signals of interest in mammalian cells.
84. M. Kushwaha, W. Rostain, S. Prakash, J.N. Duncan and A. Jaramillo, Using RNA as molecular code for programming cellular function, *ACS Synth Biol* **5**, 2016, 795-809. [Comprehensive](#) [Comprehensive](#) review on RNA engineering and programmability including RNA parts, methods and computational models for rationally designed synthetic biology.
85. W. Tang, J.H. Hu and D.R. Liu, Aptazyme-embedded guide RNAs enable ligand-responsive genome editing and transcriptional activation, *Nat Commun* **8**, 2017, 15939. [First](#) [First](#) designs of ligand-responsive aptazymes incorporated into CRISPR-sgRNAs for small molecule-controlled genome editing and transcriptional activation in mammalian cells.
86. Q.R.V. Ferry, R. Lyutova and T.A. Fulga, Rational design of inducible CRISPR guide RNAs for de novo assembly of transcriptional programs, *Nat Commun* **8**, 2017. [Designs](#) [Designs](#) of ligand-controlled spacer-blocking hairpin (SBH) structures at the 5' end of CRISPR-sgRNAs to abrogate the function of CRISPR-transcriptional activators and induce conditional activation in response to genetically encoded or external triggers.
87. H.-W. Lee, S.G. Robinson, S. Bandyopadhyay, R.H. Mitchell and D. Sen, Reversible photo-regulation of a hammerhead ribozyme using a diffusible effector, *J Mol Biol* **371**, 2007, 1163-1173.
88. J. Roßmanith and F. Narberhaus, Exploring the modular nature of riboswitches and RNA thermometers, *Nucleic Acids Res* **44**, 2016, 5410-5423. [Establishment](#) [Establishment](#) of the first RNA thermometer for the control of transcription.
89. F.J. Isaacs, D.J. Dwyer, C. Ding, D.D. Perovuchine, C.R. Cantor and J.J. Collins, Engineered riboregulators enable post-transcriptional control of gene expression, *Nat Biotechnol* **22**, 2004, 841-847.
90. Y.E. Tak, B.P. Kleinstiver, J.K. Nuñez, J.Y. Hsu, J.E. Horng, J. Gong, J.S. Weissman and J.K. Joung, Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors, *Nat Methods* **14**, 2017, 1163-1166. [Engineered](#) [Engineered](#) drug-inducible catalytically inactive Cpf1 nuclease for transcriptional activation of endogenous genes in human cells.
91. R.W. Bradley, M. Buck and B. Wang, Recognizing and engineering digital-like logic gates and switches in gene regulatory networks, *Curr Opin Microbiol* **33**, 2016, 74-82.
92. M.W. Gander, J.D. Vrana, W.E. Voje, J.M. Carothers and E. Klavins, Digital logic circuits in yeast with CRISPR-dCas9 NOR gates, *Nat Commun* **8**, 2017, 15459. [Designs](#) [Designs](#) of NOR gates in *Saccharomyces cerevisiae* based on catalytically inactive dCas9 fused to the chromatin remodeller Mxi1 to construct the largest logic circuits to date.
93. A.M. Hammond and R. Galizi, Gene drives to fight malaria: current state and future directions, *Pathog Glob Health* 2018, <https://doi.org/10.1080/20477724.2018.1438880>.
94. P.D. Hsu, E.S. Lander and F. Zhang, Development and applications of CRISPR-Cas9 for genome engineering, *Cell* **157**, 2014, 1262-1278.
95. H. Wang, M.L. Russa and L.S. Qi, CRISPR/Cas9 in genome editing and beyond, *Annu Rev Biochem* **85**, 2016, 227-264.
96. R. Barrangou and J.A. Doudna, Applications of CRISPR technologies in research and beyond, *Nat Biotechnol* **34**, 2016, 933-941.
97. R. Peng, G. Lin and J. Li, Potential pitfalls of CRISPR/Cas9-mediated genome editing, *FEBS J* **283**, 2016, 1218-1231.
98. H.I. Ahmad, M.J. Ahmad, A.R. Asif, M. Adnan, M.K. Iqbal, K. Mehmood, S.A. Muhammad, A.A. Bhuiyan, A. Elokil, X. Du, et al., Review of CRISPR-Based Genome Editing: Survival, Evolution And C based genome editing: survival, evolution and challenges, *Curr Issues Mol Biol* 2018, <https://doi.org/10.21775/cimb.028.047> (looks different format from other references as non of the others include doi:... Please doublecheck.).
99. M. Adli, The CRISPR tool kit for genome editing and beyond, *Nat Commun* **9**, 2018.

## Graphical abstract

CRISPR-editors can be reprogrammed for cleavage of nucleic acids (C), transcriptional activation (A) or repression (R) and epigenetic modification (M). Examples of gRNA designs (multiplexed and cis-repressed interacting gRNA). Chemical or biological (proteins or RNAs) ligands for regulation. Computational design and testing of gRNA-ligand interactions. (The graphical abstract looks very small. Please let us



know if you may require a higher definition version of this figure)

---

## Highlights

- Riboswitches and CRISPR-editing challenges, current and future applications.
- Riboswitches can be applied to sense CRISPR-sgRNAs.
- CRISPR gRNA riboswitches can function in all kingdoms of life.
- Combined *in vivo* screening and computational analysis to improve riboswitch regulation.

---

## Queries and Answers

**Query:** The author names have been tagged as given names and surnames (surnames are highlighted in teal color). Please confirm if they have been identified correctly.

**Answer:** Yes